INSIST! Acute Myeloid Leukemia
November 2021
Insist! on Better Care
Biomarker testing in Acute Myeloid Leukemia (AML) is essential to ensure patients are receiving the best, most personalized care available. The goal of INSIST! AML is to educate and empower patients and care partners to speak up and insist on better care.
Program topics include:
Personalize Your Experience!
Create an account to save items and receive information curated just for you.
Understanding Testing in AML
AML Treatment Decisions
Your AML Navigator
This program is supported by AbbVie, Astellas, Bristol Myers Sqibb/Celgene, Daiichi-Sankyo, Foundation Medicine, Jazz, Novartis, and through generous donations from people like you.
